Technology transfer

Cambridge University is tightening its grip on rights to intellectual property generated by staff and students after academics voted overwhelmingly to endorse new plans

University tech transfer offices should stop trying to do the impossible, says Biofusion CEO David Baynes.

A new Swedish company backed by government and business angels aims to create an entire funding ecosystem for young companies until they become ready for venture capital.

Two New Year's resolutions for the governments around the world that have managed to gum up the economic machinery behind technological development.

Cambridge University wants rights to the intellectual property generated by its staff. The idea has divided scientists in a university well known for its high-tech spin-outs.

The European Commission's Clinical Trials Directive was meant to make trials more simple. But it looks as if the effect has been to stop many trials taking place at all.

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.

What are stem cells, what could they do - and why are investors wary of putting their money in them? A lay guide to the technology